<DOC>
	<DOCNO>NCT02845882</DOCNO>
	<brief_summary>The outcome child lymphoblastic lymphoma ( LBL ) China investigator ' previous study unexpected . In study , modification treatment protocol strengthen domestic multicenter collaboration , investigator try improve survival child LBL compare previous study .</brief_summary>
	<brief_title>LBL-2016 Children Adolescents China</brief_title>
	<detailed_description>The treatment LBL ALL ( acute lymphoblastic leukemia ) -based treatment . Additional , high dose L-asparaginase report improve disease-free survival patient ALL . The event free survival ( EFS ) pediatric LBL western country achieve 75 % 85 % . However , outcomes child LBL China unexpected . In previous study ( CCCG-LBL-2010 , 2009-2013 ) , 96 patient newly diagnose LBL 7 Chinese pediatric oncology center include . At median follow-up 21 month ( range , 0.3~60.7months ) , 2-year event free survival 68±5 % patient . Patients achieve complete remission day 33 induction significantly well EFS ( 77±6 % v.s.17±10 % , p &lt; 0.005 ) . In current trial , investigator try improve survival child LBL China modification treatment protocol strengthen domestic multicenter collaboration . The BFM backbone use standard backbone therapy study . Three dos daunorubicin prescribe induction compare 4 dos BFM study . Cranial radiotherapy save patient ( &gt; 2 yr ) CNS disease presentation . Complete remission ( CR ) define least 75 % tumor regression , le 5 % BM ( bone marrow ) blast , CNS ( central nervous system ) disease , disappearances evidence disease sit least 4 week . Partial response ( PR ) define &gt; 50 % tumor regression , new lesions.Response treatment evaluate day 33 day 64 induction.Patients stratify 3 risk group . Low risk group : patient ( stage I II ) receive induction protocol I follow extracompartmental protocol M , maintenance total therapy duration 96 week . Totally , 3 dos PEG-asparaginase ( Pegylated-asparaginase ) apply group . Intermediate risk group : patient ( stage III IV receive steroid within one week prior diagnosis ) receive induction protocol I follow extracompartmental protocol M , reintensification protocol II , maintenance total therapy duration 104 weeks.Totally , 5 dos PEG-asparaginase apply group . High risk group : patient ( failure qualify PR , &gt; 5 % BM blast , CNS disease d33 induction ) receive induction protocol I follow 6 intensive polychemotherapy block ( R ' ) , reintensification protocol II , maintenance total therapy duration 104 week . Totally , 11 dos PEG-asparaginase apply group . Second look biopsy/resection indicate patient without CR day 64 induction . Allo- auto-hematopoietic stem-cell transplantation recommend patient residual tumor . Patients disease progression time remove protocol therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients must newly diagnose lymphoblastic lymphoma ; Patients shall prior cytotoxic chemotherapy exception steroid ( &lt; 420mg/m2 ) Patients Down syndrome ; Morphologically unclassifiable lymphoma Patients congenital immunodeficiency , chromosomal breakage syndrome , prior organ transplantation , previous malignancy type , know positive HIV serology . Evidence pregnancy lactation period . Ph+ lymphoblastic lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>